Global Liquid Biopsy Market Share Report 2024, Forecast To 2033
16 Jan, 2024
The liquid biopsy market has experienced exponential growth, surging from $6.61 billion in 2023 to $8.64 billion in 2024, with a 30.8% CAGR. Historic growth is linked to advances in cancer research, non-invasiveness, personalized medicine, regulatory approvals, and early cancer detection. Anticipated to reach $27.44 billion in 2028, with a 33.5% CAGR, the forecast period emphasizes expanding applications, cancer monitoring, emerging technologies, companion diagnostics, and biomarker discovery. Major trends include cancer detection and monitoring, therapeutic monitoring, minimal residual disease (MRD) monitoring, and liquid biopsy in non-oncological applications.
Global Liquid Biopsy Market Key Driver
Government funds dedicated to refining cancer detection are contributing to the growth of the liquid biopsy market. The National Cancer Institute (NCI) in the USA, for instance, increased its grant monies from $570,000 in 2020 to $678,000 in 2021. With substantial funds allocated to organizations like the NCI, advancements in cancer research, diagnosis, and treatment are being accelerated, positively impacting the liquid biopsy market.
Get A Free Sample Of The Global Liquid Biopsy Market ReportGlobal Liquid Biopsy Market Segments
The liquid biopsy market covered in this report is segmented –
1) By Product: Assays Kits, Instruments, Services
2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring Orthopedics
3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers
By Geography: The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the liquid biopsy market in 2023. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Liquid Biopsy Industry Players
QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Biocept Inc., Janssen Diagnostics LLC, Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Guardant Health AMEA, Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.
Get The Full Global Liquid Biopsy Market Report
Liquid Biopsy Market Overview
A liquid biopsy is a quick and painless substitute for surgical biopsies that allows medical professionals to learn a lot about a tumor from a small blood sample. A liquid biopsy is a diagnostic test performed on blood to detect the presence of any cancerous cells in the blood. It is used to detect cancer at an early stage.
Liquid Biopsy Global Market Report 2023 provides data on the global liquid biopsy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The liquid biopsy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.